The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 5, 2012
ICON Selected by Roche for Technology Partnership
Advertisement
Roche is using ICON’s MIRA (Medical Image Review and Analysis) software as the company’s central repository for medical images. MIRA is the core application used by ICON Medical Imaging in its daily operations and provides functionality for imaging and clinical data management, image analysis, project management and document management. MIRA is being implemented by Roche in a Software as a Service (SaaS) model, which provides Roche with 24/7 access to imaging data from anywhere in the world and also eliminates the technology costs associated with purchasing and maintaining an image management system in-house. ICON is the first medical imaging provider to offer clients a SaaS solution for their image management needs.
Commenting on the partnership, Dr. Gudrun Zahlman, Leader Imaging Infrastructure at Roche, commented, “We committed to ICON and MIRA after a one year pilot program. The comprehensive functionality of MIRA, the US and EU redundancy of the data, and the responsive nature of the ICON staff, proved the best fit for Roche’s needs. Additionally, we have achieved the seamless integration of images hosted in MIRA with Roche’s clinical data repository and data mining tools for trial decision making, and have integrated 3rd party image analysis software within MIRA for quantitative biomarker research.”
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5